<p>軟銀集團在最近向美國證券交易委員會提交的文件中表示，在第四季度將其在 Neumora Therapeutics, Inc.（NASDAQ:NMRA - 免費報告）中的持倉減少了 13.3%。該機構投資者在此期間出售了 1,005,726 股後，持有 6,541,190 股該公司的股票。Neumora Therapeutics 佔軟銀集團投資組合的 0.3%，使其成為該公司第 12 大持倉。軟銀集團在最近的報告期末持有約 4.05% 的 Neumora Therapeutics，價值 69,337,000 美元。</p>
<p>獲取 <strong>Neumora Therapeutics</strong> 的提醒：</p>
<p>其他幾家對沖基金最近也對該公司的持倉進行了調整。資本國際投資者在第四季度將其在 Neumora Therapeutics 的股份增加了 692.1%。資本國際投資者現在持有 3,700,359 股該公司的股票，價值 39,224,000 美元，此前在上個季度又購買了 3,233,179 股。Schonfeld 戰略顧問公司在第四季度將其在 Neumora Therapeutics 的持倉增加了 273.9%。Schonfeld 戰略顧問公司現在持有 521,013 股該公司的股票，價值 5,523,000 美元，此前在上個季度又購買了 381,676 股。先鋒集團在第四季度將其在 Neumora Therapeutics 的股份增加了 4.5%。先鋒集團現在持有 4,572,308 股該公司的股票，價值 48,466,000 美元，此前在此期間又收購了 195,142 股。Cutter 資本管理公司在第四季度以 1,590,000 美元的估值購買了 Neumora Therapeutics 的新股份。最後，Rock Springs 資本管理公司在第四季度將其在 Neumora Therapeutics 的持倉增加了 15.3%。Rock Springs 資本管理公司現在持有 955,106 股該公司的股票，價值 10,124,000 美元，此前在上個季度又購買了 127,005 股。47.65% 的股票由機構投資者持有。</p>
<h2>分析師評級調整</h2>
<p>幾位研究分析師對 NMRA 股票發表了看法。Guggenheim 在 3 月 7 日的報告中將 Neumora Therapeutics 的股票評級從 “買入” 下調至 “中性”。加拿大皇家銀行在 3 月 4 日的報告中重申了 “行業表現” 評級，並對 Neumora Therapeutics 的股票設定了 4.00 美元的目標價。Needham &amp; Company LLC 在週二重申了 “買入” 評級，並對 Neumora Therapeutics 的股票設定了 5.00 美元的目標價。HC Wainwright 在 3 月 4 日的研究報告中將 Neumora Therapeutics 的目標價從 30.00 美元下調至 18.00 美元，並對該公司設定了 “買入” 評級。最後，William Blair 在 3 月 10 日的研究報告中將 Neumora Therapeutics 的股票評級從 “跑贏大盤” 下調至 “市場表現”。一位投資分析師對該股票給予了賣出評級，五位給予了持有評級，三位給予了買入評級。根據 MarketBeat 的數據，Neumora Therapeutics 目前的共識評級為 “持有”，平均目標價為 9.29 美元。</p>
<p><strong>查看我們對 Neumora Therapeutics 的最新分析</strong></p>
<h2>Neumora Therapeutics 股價上漲 8.2%</h2>
<p>Neumora Therapeutics 的股票在週五開盤價為 0.67 美元。該股票的 50 日移動平均價格為 0.86 美元，200 日移動平均價格為 4.42 美元。Neumora Therapeutics, Inc.的 12 個月低點為 0.61 美元，12 個月高點為 17.19 美元。該公司的市值為 1.0769 億美元，市盈率為-0.36，貝塔值為 2.96。</p>
<p>Neumora Therapeutics（NASDAQ:NMRA - 獲取免費報告）最近於 5 月 12 日發佈了季度財報。該公司報告每股收益（EPS）為-0.42 美元，低於市場共識預期的-0.40 美元，差距為-0.02 美元。整體來看，分析師預測 Neumora Therapeutics, Inc.在當前財年將發佈-1.61 的每股收益。</p>
<h2>Neumora Therapeutics 簡介</h2>
<p>（免費報告）</p>
<p>Neumora Therapeutics, Inc.是一家臨牀階段的生物製藥公司，專注於開發針對腦疾病、神經精神疾病和神經退行性疾病的治療方案。該公司開發的 navacaprant（NMRA-140）是一種新型的每日一次口服的κ-阿片受體拮抗劑，目前正在進行針對重度抑鬱症的第三階段臨牀試驗。</p>
<h2>瞭解更多</h2>
<ul>
<li>我們更看好的五隻股票，而非 Neumora Therapeutics</li>
<li>現在值得購買的 2 只金融科技股票和 1 只應避免的股票</li>
<li>CRSPR 股票可能準備兑現其巨大的承諾</li>
<li>債券市場假期是什麼？如何投資和交易</li>
<li>分析師和機構繼續大舉押注 Alphabet</li>
<li>股票交易：相對強弱指數及其用途</li>
<li>沃爾瑪股票提醒：預計近期將有大幅價格波動</li>
</ul>
<p><strong>想看看其他對沖基金持有的 NMRA 股票嗎？</strong> 訪問 HoldingsChannel.com，獲取 Neumora Therapeutics, Inc.（NASDAQ:NMRA - 免費報告）的最新 13F 文件和內部交易信息。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Tk1SQQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Tk1SQQ"/></p>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前經過 MarketBeat 編輯團隊的審核。如對該故事有任何問題或意見，請發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 Neumora Therapeutics 嗎？</h2>
<p>在考慮 Neumora Therapeutics 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前購買……而 Neumora Therapeutics 並不在名單上。</p>
<p>雖然 Neumora Therapeutics 目前在分析師中獲得 “持有” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>查看這五隻股票的詳情</p>

NMRA

<p>軟銀集團在 2023 年第四季度減少了對 Neumora Therapeutics, Inc.（納斯達克代碼：NMRA）13.3% 的持股，目前持有 6,541,190 股，價值 6934 萬美元。這使得 Neumora 佔其投資組合的 0.3%。其他對沖基金也調整了他們的持倉，國際資本投資者的持股增加了 692.1%。分析師對 NMRA 的評級不一，普遍評級為 “持有”，平均目標價為 9.29 美元。Neumora 的股票目前交易價格為 0.67 美元，較 12 個月高點 17.19 美元下跌</p>

<p>Softbank Group CORP. decreased its position in Neumora Therapeutics, Inc. (NASDAQ:NMRA - Free Report) by 13.3% during the 4th quarter, according to its most recent filing with the SEC. The institutional investor owned 6,541,190 shares of the company's stock after selling 1,005,726 shares during the period. Neumora Therapeutics comprises 0.3% of Softbank Group CORP.'s portfolio, making the stock its 12th biggest position. Softbank Group CORP. owned about 4.05% of Neumora Therapeutics worth $69,337,000 at the end of the most recent reporting period.</p>
<div class="lb-trans"><p>軟銀集團在最近向美國證券交易委員會提交的文件中表示，在第四季度將其在 Neumora Therapeutics, Inc.（NASDAQ:NMRA - 免費報告）中的持倉減少了 13.3%。該機構投資者在此期間出售了 1,005,726 股後，持有 6,541,190 股該公司的股票。Neumora Therapeutics 佔軟銀集團投資組合的 0.3%，使其成為該公司第 12 大持倉。軟銀集團在最近的報告期末持有約 4.05% 的 Neumora Therapeutics，價值 69,337,000 美元。</p>
</div><p>Get <strong>Neumora Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Neumora Therapeutics</strong> 的提醒：</p>
</div><p>Several other hedge funds also recently made changes to their positions in the business. Capital International Investors raised its stake in shares of Neumora Therapeutics by 692.1% during the 4th quarter. Capital International Investors now owns 3,700,359 shares of the company's stock worth $39,224,000 after purchasing an additional 3,233,179 shares in the last quarter. Schonfeld Strategic Advisors LLC lifted its position in shares of Neumora Therapeutics by 273.9% in the fourth quarter. Schonfeld Strategic Advisors LLC now owns 521,013 shares of the company's stock valued at $5,523,000 after buying an additional 381,676 shares during the last quarter. Vanguard Group Inc. boosted its stake in shares of Neumora Therapeutics by 4.5% during the 4th quarter. Vanguard Group Inc. now owns 4,572,308 shares of the company's stock worth $48,466,000 after acquiring an additional 195,142 shares during the period. Cutter Capital Management LP bought a new stake in Neumora Therapeutics in the 4th quarter valued at $1,590,000. Finally, Rock Springs Capital Management LP increased its holdings in shares of Neumora Therapeutics by 15.3% in the fourth quarter. Rock Springs Capital Management LP now owns 955,106 shares of the company's stock valued at $10,124,000 after purchasing an additional 127,005 shares during the last quarter. 47.65% of the stock is owned by institutional investors.</p>
<div class="lb-trans"><p>其他幾家對沖基金最近也對該公司的持倉進行了調整。資本國際投資者在第四季度將其在 Neumora Therapeutics 的股份增加了 692.1%。資本國際投資者現在持有 3,700,359 股該公司的股票，價值 39,224,000 美元，此前在上個季度又購買了 3,233,179 股。Schonfeld 戰略顧問公司在第四季度將其在 Neumora Therapeutics 的持倉增加了 273.9%。Schonfeld 戰略顧問公司現在持有 521,013 股該公司的股票，價值 5,523,000 美元，此前在上個季度又購買了 381,676 股。先鋒集團在第四季度將其在 Neumora Therapeutics 的股份增加了 4.5%。先鋒集團現在持有 4,572,308 股該公司的股票，價值 48,466,000 美元，此前在此期間又收購了 195,142 股。Cutter 資本管理公司在第四季度以 1,590,000 美元的估值購買了 Neumora Therapeutics 的新股份。最後，Rock Springs 資本管理公司在第四季度將其在 Neumora Therapeutics 的持倉增加了 15.3%。Rock Springs 資本管理公司現在持有 955,106 股該公司的股票，價值 10,124,000 美元，此前在上個季度又購買了 127,005 股。47.65% 的股票由機構投資者持有。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析師評級調整</h2>
</div><p>Several research analysts have weighed in on NMRA shares. Guggenheim cut shares of Neumora Therapeutics from a &#34;buy&#34; rating to a &#34;neutral&#34; rating in a report on Friday, March 7th. Royal Bank of Canada reissued a &#34;sector perform&#34; rating and issued a $4.00 price objective on shares of Neumora Therapeutics in a report on Tuesday, March 4th. Needham &amp; Company LLC reaffirmed a &#34;buy&#34; rating and issued a $5.00 price objective on shares of Neumora Therapeutics in a report on Tuesday. HC Wainwright cut their price objective on shares of Neumora Therapeutics from $30.00 to $18.00 and set a &#34;buy&#34; rating for the company in a research report on Tuesday, March 4th. Finally, William Blair cut shares of Neumora Therapeutics from an &#34;outperform&#34; rating to a &#34;market perform&#34; rating in a research report on Monday, March 10th. One investment analyst has rated the stock with a sell rating, five have given a hold rating and three have given a buy rating to the company's stock. Based on data from MarketBeat, Neumora Therapeutics currently has a consensus rating of &#34;Hold&#34; and an average price target of $9.29.</p>
<div class="lb-trans"><p>幾位研究分析師對 NMRA 股票發表了看法。Guggenheim 在 3 月 7 日的報告中將 Neumora Therapeutics 的股票評級從 “買入” 下調至 “中性”。加拿大皇家銀行在 3 月 4 日的報告中重申了 “行業表現” 評級，並對 Neumora Therapeutics 的股票設定了 4.00 美元的目標價。Needham &amp; Company LLC 在週二重申了 “買入” 評級，並對 Neumora Therapeutics 的股票設定了 5.00 美元的目標價。HC Wainwright 在 3 月 4 日的研究報告中將 Neumora Therapeutics 的目標價從 30.00 美元下調至 18.00 美元，並對該公司設定了 “買入” 評級。最後，William Blair 在 3 月 10 日的研究報告中將 Neumora Therapeutics 的股票評級從 “跑贏大盤” 下調至 “市場表現”。一位投資分析師對該股票給予了賣出評級，五位給予了持有評級，三位給予了買入評級。根據 MarketBeat 的數據，Neumora Therapeutics 目前的共識評級為 “持有”，平均目標價為 9.29 美元。</p>
</div><p><strong>Check Out Our Latest Analysis on Neumora Therapeutics</strong></p>
<div class="lb-trans"><p><strong>查看我們對 Neumora Therapeutics 的最新分析</strong></p>
</div><h2>Neumora Therapeutics Trading Up 8.2%</h2>
<div class="lb-trans"><h2>Neumora Therapeutics 股價上漲 8.2%</h2>
</div><p>Neumora Therapeutics stock opened at $0.67 on Friday. The stock has a 50-day moving average price of $0.86 and a two-hundred day moving average price of $4.42. Neumora Therapeutics, Inc. has a 12 month low of $0.61 and a 12 month high of $17.19. The company has a market capitalization of $107.69 million, a PE ratio of -0.36 and a beta of 2.96.</p>
<div class="lb-trans"><p>Neumora Therapeutics 的股票在週五開盤價為 0.67 美元。該股票的 50 日移動平均價格為 0.86 美元，200 日移動平均價格為 4.42 美元。Neumora Therapeutics, Inc.的 12 個月低點為 0.61 美元，12 個月高點為 17.19 美元。該公司的市值為 1.0769 億美元，市盈率為-0.36，貝塔值為 2.96。</p>
</div><p>Neumora Therapeutics (NASDAQ:NMRA - Get Free Report) last released its quarterly earnings results on Monday, May 12th. The company reported ($0.42) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.40) by ($0.02). As a group, analysts predict that Neumora Therapeutics, Inc. will post -1.61 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>Neumora Therapeutics（NASDAQ:NMRA - 獲取免費報告）最近於 5 月 12 日發佈了季度財報。該公司報告每股收益（EPS）為-0.42 美元，低於市場共識預期的-0.40 美元，差距為-0.02 美元。整體來看，分析師預測 Neumora Therapeutics, Inc.在當前財年將發佈-1.61 的每股收益。</p>
</div><h2>Neumora Therapeutics Profile</h2>
<div class="lb-trans"><h2>Neumora Therapeutics 簡介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免費報告）</p>
</div><p>Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.</p>
<div class="lb-trans"><p>Neumora Therapeutics, Inc.是一家臨牀階段的生物製藥公司，專注於開發針對腦疾病、神經精神疾病和神經退行性疾病的治療方案。該公司開發的 navacaprant（NMRA-140）是一種新型的每日一次口服的κ-阿片受體拮抗劑，目前正在進行針對重度抑鬱症的第三階段臨牀試驗。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>瞭解更多</h2>
</div><ul>
<li>Five stocks we like better than Neumora Therapeutics</li>
<li>2 Fintech Stocks to Buy Now and 1 to Avoid</li>
<li>CRSPR Stock Could Be Ready to Deliver on Its Massive Promise</li>
<li>What is a Bond Market Holiday? How to Invest and Trade</li>
<li>Analysts and Institutions Continue to Bet Big on Alphabet</li>
<li>Trading Stocks: RSI and Why it's Useful</li>
<li>Walmart Stock Alert: Big Price Move Expected Soon</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票，而非 Neumora Therapeutics</li>
<li>現在值得購買的 2 只金融科技股票和 1 只應避免的股票</li>
<li>CRSPR 股票可能準備兑現其巨大的承諾</li>
<li>債券市場假期是什麼？如何投資和交易</li>
<li>分析師和機構繼續大舉押注 Alphabet</li>
<li>股票交易：相對強弱指數及其用途</li>
<li>沃爾瑪股票提醒：預計近期將有大幅價格波動</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding NMRA?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Neumora Therapeutics, Inc. (NASDAQ:NMRA - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他對沖基金持有的 NMRA 股票嗎？</strong> 訪問 HoldingsChannel.com，獲取 Neumora Therapeutics, Inc.（NASDAQ:NMRA - 免費報告）的最新 13F 文件和內部交易信息。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Tk1SQQ" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=NMRA"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前經過 MarketBeat 編輯團隊的審核。如對該故事有任何問題或意見，請發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Neumora Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Neumora Therapeutics 嗎？</h2>
</div><p>Before you consider Neumora Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Neumora Therapeutics 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Neumora Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前購買……而 Neumora Therapeutics 並不在名單上。</p>
</div><p>While Neumora Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Neumora Therapeutics 目前在分析師中獲得 “持有” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看這五隻股票的詳情</p>
</div>

軟銀集團公司在 Neumora Therapeutics, Inc.（NASDAQ:NMRA）持有價值 6934 萬美元的頭寸